In a retrospective analysis of de-identified data from 2,138 patients, Adaptive Biotechnologies’ clonoSEQ^® next-generation sequencing MRD assay identified trackable DNA sequences in 91.2% of patients with acute lymphoblastic leukemia (ALL) or multiple myeloma (MM) using the Clonality (ID) test.

Among 2,073 patients assessed for MRD, 78.4% of those with ALL and 47.5% of those with MM achieved MRD levels below 10^-5, with 68.7% of ALL patients and 30.6% of MM patients achieving levels below 10^-6.

“The ability to capture and report patient MRD values using a quantitative and standardized assay in a large real-world population presents important opportunities for understanding lymphoid cancer population health and performing comparative effectiveness and other [real-world evidence] studies,” the study authors wrote.

• Demaree A, Hewitt A, Eckert B, et al. Real-World Minimal Residual Disease (MRD) Assessment and Trends Using clonoSEQ in Acute Lymphoblastic Leukemia and Multiple Myeloma. Presented at: 2020 NCCN Virtual Annual Meeting; March 20–22, 2020: Orlando, FL, United States. Abstract 92. [see attached PDF]

Tags: MRD, patient care